Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
mipletamig
product4 mentionslast seen Nov 12, 2026
Bispecific immunotherapy designed to redirect the immune system to destroy leukemic cells expressing CD123.
Relationships 7
- mipletamigapplies toacute myeloid leukemia treatment99% confidence4 sources
- Aptevo Therapeutics Inc.developsmipletamig99% confidence4 sources
- mipletamigdepends onazacitidine99% confidence2 sources
- mipletamigdepends onvenetoclax99% confidence2 sources
- mipletamigconforms toOrphan Drug designation92% confidence1 source
- mipletamigdepends onCRIS-7-derived CD3 binding pathway90% confidence1 source
- mipletamigconforms toOrphan Drug Act designation90% confidence1 source
Relationship
mipletamigapplies toacute myeloid leukemia treatment
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- filingSEC EDGARNov 12, 2026Aptevo Therapeutics Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia
- filingSEC EDGARNov 9, 2026Aptevo Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia
- filingSEC EDGARNov 5, 2026Aptevo Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Mipletamig is being evaluated in combination with standard-of-care venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy
- filingSEC EDGAROct 26, 2026Aptevo Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
mipletamig, is being evaluated for the treatment of AML